Back to Search Start Over

PGM3 insufficiency: a glycosylation disorder causing a notable T cell defect.

Authors :
Yang L
Zerbato B
Pessina A
Brambilla L
Andreani V
Frey-Jakobs S
Fliegauf M
Barbouche MR
Zhang Q
Chiaradonna F
Proietti M
Du X
Grimbacher B
Source :
Frontiers in immunology [Front Immunol] 2024 Dec 24; Vol. 15, pp. 1500381. Date of Electronic Publication: 2024 Dec 24 (Print Publication: 2024).
Publication Year :
2024

Abstract

Background: Hypomorphic mutations in the phosphoacetylglucosamine mutase 3 ( PGM3 ) gene cause a glycosylation disorder that leads to immunodeficiency. It is often associated with recurrent infections and atopy. The exact etiology of this condition remains unclear.<br />Objective: This study aimed to characterize the phenotypes and immunological features associated with PGM3 insufficiency and investigate potential disease mechanisms.<br />Methods: A systematic review of 44 published cases of PGM3 variants was performed, followed by T-cell phenotyping of two patients with PGM3 variants. A genotype-phenotypic severity study was conducted by comparing the residual PGM3 expression of the 12 reconstituted variants in human B cells. A PGM3 inhibitor was used to assess its effect on CD4+ T cell proliferation and differentiation.<br />Results: Patients with PGM3 variants frequently presented with recurrent infections and atopy, accompanied by reduced naïve CD4+ T cell counts. A genotype-phenotype study showed that low levels of residual PGM3 expression are correlated with disease severity. Notably, inhibition of PGM3 activity impaired TCR-mediated CD4+ T cell proliferation and the synthesis of UDP-GlcNAc, complex N-glycans, O-GlcNAc, glycolytic stress, and mitochondrial respiration during proliferation in a dose-dependent manner. Partial loss of PGM3 activity was observed to preferentially enhance Th1 and Th2 differentiation, while attenuating Th17 and Treg differentiation, consistent with clinical observations.<br />Conclusion: PGM3 is a critical regulator of CD4+ T-cell proliferation and differentiation. These findings provide new insights into the diverse clinical manifestations and therapeutic development of PGM3 deficiency.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2024 Yang, Zerbato, Pessina, Brambilla, Andreani, Frey-Jakobs, Fliegauf, Barbouche, Zhang, Chiaradonna, Proietti, Du and Grimbacher.)

Details

Language :
English
ISSN :
1664-3224
Volume :
15
Database :
MEDLINE
Journal :
Frontiers in immunology
Publication Type :
Academic Journal
Accession number :
39776909
Full Text :
https://doi.org/10.3389/fimmu.2024.1500381